Akebia Gets FibroGen Anemia Drug Patents Invalidated In UK
A London judge on Monday invalidated five patents covering FibroGen Inc.'s anemia treatments and found that Akebia Therapeutics Inc. did not infringe its competitor's sixth patent, ruling that most of the...To view the full article, register now.
Already a subscriber? Click here to view full article